JP6675334B2 - 脊髄性筋萎縮症を処置するためのイミダゾ［１，２−ａ］ピラジン−１−イルベンズアミド化合物 - Google Patents
脊髄性筋萎縮症を処置するためのイミダゾ［１，２−ａ］ピラジン−１−イルベンズアミド化合物 Download PDFInfo
- Publication number
- JP6675334B2 JP6675334B2 JP2016575151A JP2016575151A JP6675334B2 JP 6675334 B2 JP6675334 B2 JP 6675334B2 JP 2016575151 A JP2016575151 A JP 2016575151A JP 2016575151 A JP2016575151 A JP 2016575151A JP 6675334 B2 JP6675334 B2 JP 6675334B2
- Authority
- JP
- Japan
- Prior art keywords
- pyrazin
- methylimidazo
- benzamide
- fluoro
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *c1c[n](cc(N(*)*(C2=C(*)C(*)=C(*)**2)=O)nc2*I)c2n1 Chemical compound *c1c[n](cc(N(*)*(C2=C(*)C(*)=C(*)**2)=O)nc2*I)c2n1 0.000 description 2
- QNTAZZYFWSJYGH-DEOSSOPVSA-N CCOc1cc(N2C[C@](C)(CCC3)N3CC2)ccc1C(Nc(nc1)c[n]2c1nc(C)c2)=O Chemical compound CCOc1cc(N2C[C@](C)(CCC3)N3CC2)ccc1C(Nc(nc1)c[n]2c1nc(C)c2)=O QNTAZZYFWSJYGH-DEOSSOPVSA-N 0.000 description 1
- PUPVOQQAWUMQFM-GFCCVEGCSA-N C[C@H](CN(CC1)c2ccc(C(OC)=O)c(F)c2)N1C(OC(C)(C)C)=O Chemical compound C[C@H](CN(CC1)c2ccc(C(OC)=O)c(F)c2)N1C(OC(C)(C)C)=O PUPVOQQAWUMQFM-GFCCVEGCSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14173935 | 2014-06-25 | ||
| EP14173935.9 | 2014-06-25 | ||
| PCT/EP2015/063894 WO2015197503A1 (en) | 2014-06-25 | 2015-06-22 | Imidazo[1,2-a]pyrazin-1yl-benzamide compounds for treating spinal muscular atrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017520570A JP2017520570A (ja) | 2017-07-27 |
| JP6675334B2 true JP6675334B2 (ja) | 2020-04-01 |
Family
ID=50980240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016575151A Active JP6675334B2 (ja) | 2014-06-25 | 2015-06-22 | 脊髄性筋萎縮症を処置するためのイミダゾ［１，２−ａ］ピラジン−１−イルベンズアミド化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9975900B2 (https=) |
| EP (1) | EP3160967B1 (https=) |
| JP (1) | JP6675334B2 (https=) |
| KR (1) | KR102565544B1 (https=) |
| CN (1) | CN106459067B (https=) |
| BR (1) | BR112016026951B1 (https=) |
| CA (1) | CA2952895C (https=) |
| MX (1) | MX375925B (https=) |
| RU (1) | RU2725979C2 (https=) |
| WO (1) | WO2015197503A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015024876A2 (en) | 2013-08-19 | 2015-02-26 | F. Hoffmann-La Roche Ag | Screening method |
| IL294124B2 (en) | 2015-12-10 | 2024-02-01 | Ptc Therapeutics Inc | Methods for treating huntington's disease |
| US11407753B2 (en) | 2017-06-05 | 2022-08-09 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| WO2019005993A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | METHODS OF TREATING HUNTINGTON'S DISEASE |
| US11382918B2 (en) | 2017-06-28 | 2022-07-12 | Ptc Therapeutics, Inc. | Methods for treating Huntington's Disease |
| KR102740831B1 (ko) | 2017-11-14 | 2024-12-11 | 칠드런'즈 메디컬 센터 코포레이션 | 신규 이미다조피리미딘 화합물 및 그의 용도 |
| EP3710007A4 (en) | 2017-11-14 | 2021-12-15 | Children's Medical Center Corporation | USE OF IMIDAZOPYRIMIDINE TO MODULATE HUMAN IMMUNE RESPONSE |
| MX2020009957A (es) | 2018-03-27 | 2021-01-15 | Ptc Therapeutics Inc | Compuestos para el tratamiento de enfermedad de hungtinton. |
| EP3814360B8 (en) | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| EP3814345B8 (en) | 2018-06-27 | 2024-10-30 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| BR112020026637A2 (pt) | 2018-06-27 | 2021-03-30 | Reborna Biosciences, Inc. | Agente profilático ou terapêutico para atrofia muscular espinhal |
| PL3814357T3 (pl) | 2018-06-27 | 2024-09-16 | Ptc Therapeutics, Inc. | Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona |
| MA54755A (fr) * | 2019-01-18 | 2021-11-24 | Biogen Ma Inc | Dérivés d'imidazo[1,2-a]pyridinyle servant d'inhibiteurs d'irak4 |
| WO2020231977A1 (en) | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| WO2021007378A1 (en) | 2019-07-11 | 2021-01-14 | Ptc Therapeutics, Inc. | Compounds for use in treating huntington's disease |
| JP7736700B2 (ja) * | 2020-02-28 | 2025-09-09 | リミックス セラピューティクス インコーポレイテッド | 複素環アミド及びスプライシングを調節するためのその使用 |
| BR112022023025A2 (pt) * | 2020-05-13 | 2023-03-28 | Chdi Foundation Inc | Moduladores de htt para tratar doença de huntington |
| US20250018046A1 (en) * | 2021-07-07 | 2025-01-16 | Biogen Ma Inc | Compounds for targeting degradation of irak4 proteins |
| US12281116B2 (en) | 2021-11-17 | 2025-04-22 | Chdi Foundation, Inc. | HTT modulators for treating Huntington's disease |
| CN118748995A (zh) * | 2021-12-03 | 2024-10-08 | 亚根达医疗公司 | 5-嘧啶甲酰胺衍生物和其使用方法 |
| AR132351A1 (es) | 2023-04-13 | 2025-06-18 | Syngenta Crop Protection Ag | Derivados de imidazo[1,2-a]pirazina |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005085252A1 (en) * | 2004-03-04 | 2005-09-15 | Biofocus Discovery Limited | Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases |
| MX2009013213A (es) * | 2007-06-08 | 2010-03-30 | Abbott Lab | Indazoles 5-sustituidos 5-heteroarilo como inhibidores de cinasa. |
| CA2821817A1 (en) * | 2010-12-17 | 2012-06-21 | Bayer Intellectual Property Gmbh | Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| KR102057351B1 (ko) * | 2011-12-30 | 2019-12-18 | 피티씨 테라퓨틱스, 인크. | 척수성 근위축증을 치료하기 위한 화합물 |
| PE20150224A1 (es) * | 2012-05-11 | 2015-03-08 | Abbvie Inc | Inhibidores del nampt |
| US9212209B2 (en) * | 2012-07-13 | 2015-12-15 | Indiana University Research And Technology Corporation | Screening methods for spinal muscular atrophy |
| GB201212513D0 (en) * | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| EP2920177A1 (en) * | 2012-11-19 | 2015-09-23 | Novartis AG | Compounds and compositions for the treatment of parasitic diseases |
| WO2014209841A2 (en) * | 2013-06-25 | 2014-12-31 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
-
2015
- 2015-06-22 BR BR112016026951-9A patent/BR112016026951B1/pt active IP Right Grant
- 2015-06-22 KR KR1020177002082A patent/KR102565544B1/ko active Active
- 2015-06-22 MX MX2016015248A patent/MX375925B/es active IP Right Grant
- 2015-06-22 EP EP15729520.5A patent/EP3160967B1/en active Active
- 2015-06-22 CN CN201580031914.7A patent/CN106459067B/zh active Active
- 2015-06-22 RU RU2017102014A patent/RU2725979C2/ru active
- 2015-06-22 WO PCT/EP2015/063894 patent/WO2015197503A1/en not_active Ceased
- 2015-06-22 JP JP2016575151A patent/JP6675334B2/ja active Active
- 2015-06-22 CA CA2952895A patent/CA2952895C/en active Active
-
2016
- 2016-12-14 US US15/379,057 patent/US9975900B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3160967A1 (en) | 2017-05-03 |
| CA2952895C (en) | 2023-09-26 |
| EP3160967B1 (en) | 2019-05-08 |
| JP2017520570A (ja) | 2017-07-27 |
| RU2017102014A (ru) | 2018-07-27 |
| MX375925B (es) | 2025-03-07 |
| BR112016026951A2 (https=) | 2017-08-15 |
| CA2952895A1 (en) | 2015-12-30 |
| RU2725979C2 (ru) | 2020-07-08 |
| US20170197969A1 (en) | 2017-07-13 |
| CN106459067B (zh) | 2019-05-31 |
| KR102565544B1 (ko) | 2023-08-10 |
| CN106459067A (zh) | 2017-02-22 |
| MX2016015248A (es) | 2017-02-23 |
| RU2017102014A3 (https=) | 2019-01-22 |
| KR20170018076A (ko) | 2017-02-15 |
| US9975900B2 (en) | 2018-05-22 |
| WO2015197503A1 (en) | 2015-12-30 |
| BR112016026951B1 (pt) | 2022-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6675334B2 (ja) | 脊髄性筋萎縮症を処置するためのイミダゾ［１，２−ａ］ピラジン−１−イルベンズアミド化合物 | |
| US10501482B2 (en) | Compounds for treating spinal muscular atrophy | |
| JP6236173B2 (ja) | 脊髄性筋萎縮症を処置するための化合物 | |
| JP6749343B2 (ja) | 脊髄性筋萎縮症を処置するための化合物 | |
| US11827646B2 (en) | Compounds for treating spinal muscular atrophy | |
| HK1230198B (zh) | 用於治疗脊髓性肌萎缩的咪唑并[1，2-a]吡嗪-1基苯甲酰胺化合物 | |
| HK1230198A1 (en) | Imidazo[1,2-a]pyrazin-1yl-benzamide compounds for treating spinal muscular atrophy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180615 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190221 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190312 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190530 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190724 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190911 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200212 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200310 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6675334 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |